Study of JYP0061 for acute NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with neuromyelitis optica spectrum disorder (NMOSD) using the 2015 criteria.
- You must have a positive test for the AQP4 antibody (a specific marker for NMOSD).
- You must be currently having an acute (sudden) attack or worsening of NMOSD symptoms.
- You cannot be pregnant or breastfeeding, and must agree to use two forms of birth control (non-oral) for 6 months after the last dose.
- You cannot be allergic to any ingredient in the study drug, and you must be able to have an MRI with contrast dye.
- Your symptoms must not have started improving before you receive the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.